Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?

被引：15
作者：
Lisco, Giuseppe [1 ]
De Tullio, Anna [1 ]
Disoteo, Olga [2 ]
Piazzolla, Giuseppina [1 ]
Guastamacchia, Edoardo [1 ]
Sabba, Carlo [1 ]
De Geronimo, Vincenzo [3 ]
Papini, Enrico [4 ]
Triggiani, Vincenzo [1 ]
机构：
[1] Univ Bari Aldo Moro, Sch Med, Interdisciplinary Dept Med, Sect Internal Med Geriatr Endocrinol & Rare Dis, Piazza Giulio Cesare, Bari, Italy
[2] ASST Grande Osped Metropolitano Niguarda, Diabetol Unit, Milan, Italy
[3] Policlin Morgagni CCD, Unit Endocrinol, Catania, Italy
[4] Regina Apostolorum Hosp, Dept Endocrinol & Metab, Rome, Italy
来源：
ENDOCRINE CONNECTIONS | 2023年 / 12卷 / 11期
基金：
英国科研创新办公室;
关键词：
dipeptidyl peptidase IV; glucagon-like peptide 1 receptor agonist; incretin system; medullary thyroid cancer; papillary thyroid cancer; GLP-1; RECEPTOR; CALCITONIN CONCENTRATIONS; LIRAGLUTIDE; RISK; IV; METASTASIS; EXPRESSION; BENEFITS; INCREASE; OBESITY;
D O I：
10.1530/EC-23-0257
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.
引用
收藏
页数：7
相关论文
共 61 条
  • [1] Thyroid Cancer Screening in South Korea Increases Detection of Papillary Cancers with No Impact on Other Subtypes or Thyroid Cancer Mortality
    Ahn, Hyeong Sik
    Kim, Hyun Jung
    Kim, Kyoung Hoon
    Lee, Young Sung
    Han, Seung Jin
    Kim, Yuri
    Ko, Min Ji
    Brito, Juan P.
    [J]. THYROID, 2016, 26 (11) : 1535 - 1540
  • [2] [Anonymous], 2023, Summary of product features: Trulicity
  • [3] The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review
    Aroda, Vanita R.
    Ratner, Robert
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2011, 27 (06) : 528 - 542
  • [4] Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
    Bethel, M. Angelyn
    Patel, Rishi A.
    Thompson, Vivian P.
    Merrill, Peter
    Reed, Shelby D.
    Li, Yanhong
    Ahmadi, Sara
    Katona, Brian G.
    Gustavson, Stephanie M.
    Ohman, Peter
    Iqbal, Nayyar
    Gagel, Robert F.
    Hernandez, Adrian F.
    Buse, John B.
    Holman, Rury R.
    [J]. DIABETES CARE, 2019, 42 (06) : 1075 - 1080
  • [5] GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
    Bezin, Julien
    Gouverneur, Amandine
    Penichon, Marine
    Mathieu, Clement
    Garrel, Renaud
    Hillaire-Buys, Dominique
    Pariente, Antoine
    Faillie, Jean-Luc
    [J]. DIABETES CARE, 2023, 46 (02) : 384 - 390
  • [6] Liraglutide and calcitonin
    Bloomgarden, Zachary
    [J]. JOURNAL OF DIABETES, 2010, 2 (04) : 223 - 224
  • [7] Minireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1
    Brubaker, Patricia L.
    [J]. ENDOCRINOLOGY, 2010, 151 (05) : 1984 - 1989
  • [8] Obesity and thyroid cancer risk
    Burrage, Lauren C.
    Mcleod, Donald S. A.
    Jordan, Susan J.
    [J]. CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2023, 30 (05) : 244 - 251
  • [9] Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
    Caparrotta, Thomas M.
    Templeton, Jack B.
    Clay, Thomas A.
    Wild, Sarah H.
    Reynolds, Rebecca M.
    Webb, David J.
    Colhoun, Helen M.
    [J]. DIABETES THERAPY, 2021, 12 (04) : 969 - 989
  • [10] A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
    Chiu, Wei-Yih
    Shih, Shyang-Rong
    Tseng, Chin-Hsiao
    [J]. EXPERIMENTAL DIABETES RESEARCH, 2012,
1234567